IntelGenx and Tetra Bio-Pharma developing dronabinol tablet

By Melissa Fassbender

- Last updated on GMT

IntelGenx and Tetra Bio-Pharma developing dronabinol tablet

Related tags Contract

IntelGenx Corp. and Tetra Bio-Pharma Inc. have signed a binding term sheet for the development and commercialization of a drug product containing dronabinol.

Under the agreement, IntelGenx will be responsible for the research and development of the product, including clinical studies and will develop the product as an oral mucoadhesive tablet based on its proprietary AdVersa® controlled-release technology, the company told us in a statement.

Next steps are FDA discussion, scale-up of the formulation, and efficacy and safety studies, Edward Miller, Director, IR & Corporate Communications, explained.

Tetra will have exclusive rights to sell the product in North America with a right of first negotiation for outside the US and Canada. The company will make non-refundable exclusive negotiation payment to IntelGenx, an upfront payment, in addition to set milestone payments.

Phase I studies have been completed and showed the mucoadhesive tablet formulation allowed for enhanced bioavailability of the synthetic THC and reduced circulatory levels of 11-OH THC.

These ph I results may translate in 1) increased efficacy and 2) reduced side effects, which remain to be proven clinically​,” Miller said.

(Features image: iStock/utah778)

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars